Anaplastic thyroid cancer: A comprehensive review of novel therapy

Expert Review of Anticancer Therapy

Volumn 11, Issue 3, 2011, Pages 387-402

  Kojic, Stefan L ^a   Strugnell, Scott S ^a   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

anaplastic thyroid cancer; novel therapy; targeted therapy; undifferentiated thyroid cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AAL 881; B RAF KINASE INHIBITOR; CETUXIMAB; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4032; POLO LIKE KINASE 1; PROTEASOME; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; RETINOIC ACID; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANALPLASTIC THYROID CANCER; ANAPLASTIC THYROID CANCER; CELL ADHESION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; MOLECULAR THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THYROID CANCER; THYROID CARCINOMA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CARCINOMA; CLINICAL TRIALS AS TOPIC; HUMANS; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 79952927806     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.179     Document Type: Review

References (124)

1. Sherman SI. Thyroid carcinoma. Lancet 361(9356), 501-511 (2003) (Pubitemid 36173719)
2. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16(1), 17-44 (2009)
3. Pinchot SN, Sippel RS, Chen H. Multitargeted approach in the treatment of thyroid cancer. Ther. Clin. Risk Manag. 4(5), 935-947 (2008)
4. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol. 14(2), 719-729 (2007) (Pubitemid 46175318)
5. Brignardello E, Gallo M, Baldi I, et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur. J. Endocrinol. 156(4), 425-430 (2007) (Pubitemid 46672642)
6. Baroli A, Pedrazzini L, Lomuscio G, Marzoli L. Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution. Minerva Endocrinol. 35(1), 9-16 (2010)
7. Chiacchio S, Lorenzoni A, Boni G, et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol. 33(4), 341-357 (2008)
8. Stenner F, Liewen H, Zweifel M, et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 99(9), 1847-1852 (2008)
9. Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14(6), 729-740 (1997) (Pubitemid 27095865)
10. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med. Chem. 7(3), 359-365 (2007) (Pubitemid 46813471)
11. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor g agonists. Lancet Oncol. 5(7), 419-429 (2004) (Pubitemid 38878045)
12. Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-g-inducible a-chemokine CXCL10 involvement in Graves? ophthalmopathy: modulation by peroxisome proliferator-activated receptor-g agonists. J. Clin. Endocrinol. Metab. 91(2), 614-620 (2006) (Pubitemid 43236933)
13. Miccoli P, Materazzi G, Antonelli A, et al. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch. Surg. 392(4), 397-404 (2007) (Pubitemid 46911411)
14. Wiseman SM, Masoudi H, Niblock P, et al. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am. J. Surg. 191(5), 581-587 (2006)
15. Wiseman SM, Loree TR, Hicks WL Jr, et al. Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction. Arch. Otolaryngol. Head Neck Surg. 129(1), 96-100 (2003) (Pubitemid 36070883)
16. Wiseman SM, Loree TR, Rigual NR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25(8), 662-670 (2003) (Pubitemid 36909751)
17. Wiseman SM, Griffith OL, Deen S, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg. 142(8), 717-727 (2007) (Pubitemid 47295728)
18. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed. Pharmacother. 62(8), 559-563 (2008)
19. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93(11), 4331-4341 (2008) (Pubitemid 352789529)
20. Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin. Endocrinol. 69(1), 148-152 (2008) (Pubitemid 351847276)
21. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clin. Prac. 2(1), 42-52 (2006)
22. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714-4719 (2008)
23. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol. 26(29), 4708-4713 (2008)
24. Volante M, Rapa I, Papotti M. Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocrine Pathol. 19(3), 150-155 (2008)
25. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28(7), 742-762 (2007) (Pubitemid 350294294)
26. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Prac. Res. 22(6), 955-969 (2008)
27. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current Opin. Cell Biol. 21(2), 296-303 (2009)
28. Mitsiades CS, Negri J, McMullan C, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol. Cancer Ther. 6(3), 1070-1078 (2007) (Pubitemid 46554578)
29. Ball DW, Jin N, Rosen DM, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab. 92(12), 4712-4718 (2007) (Pubitemid 350223448)
30. Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther. 6(6), 1785-1792 (2007) (Pubitemid 46954055)
31. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6(5), 751-759 (2008)
32. Schweppe RE, Kerege AA, Sharma V, et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid 19(8), 825-835 (2009)
33. Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr. Relat. Cancer 14(4), 957-977 (2007) (Pubitemid 351252429)
34. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol. Metab. Clin. North Am. 37(2), 375-387, viii-ix (2008) (Pubitemid 351698084)
35. Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr. Biol. 17(8), R280-R283 (2007)
36. Nappi TC, Salerno P, Zitzelsberger H, et al. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res. 69(5), 1916-1923 (2009)
37. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369(6483), 756-758 (1994)
38. Papewalis C, Wuttke M, Schinner S, et al. Role of the Novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm. Metab. Res. 41(10), 752-756 (2009)
39. Oudard S, Medioni J, Aylllon J, et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 9(6), 705-717 (2009)
40. Ensinger C, Spizzo G, Moser P, et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. NY Acad. Sci. 1030, 69-77 (2004) (Pubitemid 40378898)
41. Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J. Clin. Endocrinol. Metab. 91(9), 3662-3666 (2006) (Pubitemid 44402152)
42. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46(7), 1116-1119 (2003) (Pubitemid 36428215)
43. Hoffmann S, Burchert A, Wunderlich A, et al. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 31(2), 105-113 (2007) (Pubitemid 350195142)
44. Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res. 12(2), 600-607 (2006) (Pubitemid 43166155)
45. Lopez JP, Wang-Rodriguez J, Chang CY, et al. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope 118(8), 1372-1376 (2008)
46. Lopez JP, Wang-Rodriguez J, Chang C, et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch. Otolaryngol. Head Neck Surg. 133(10), 1022-1027 (2007) (Pubitemid 47607585)
47. Hogan T, Jing Jie Y, Williams HJ, et al. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J. Oncol. Pharm. Pract. 15(2), 111-117 (2009)
48. Pennell NA, Daniels GH, Haddad RI, et al. A Phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18(3), 317-323 (2008) (Pubitemid 351415790)
49. Fury MG, Solit DB, Su YB, et al. A Phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 59(4), 467-475 (2007) (Pubitemid 46122325)
50. Schweppe RE, Kerege AA, French JD, et al. Inhibition of Src with AZD0530 reveals the Src-Focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 94(6), 2199-2203 (2009)
51. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001) (Pubitemid 32937367)
52. O?Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Irish J. Med. Sci. 179(1), 9-15 (2010)
53. Prichard CN, Kim S, Yazici YD, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117(4), 674-679 (2007) (Pubitemid 46559046)
54. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, et al. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin. Cancer Res. 13(15 Pt 1), 4519-4527 (2007) (Pubitemid 47219722)
55. Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol. Cancer Ther. 4(4), 632-640 (2005) (Pubitemid 40601845)
56. Cooney MM, Ortiz J, Bukowski RM, Remick SC. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr. Oncol. Rep. 7(2), 90-95 (2005) (Pubitemid 40485463)
57. Mooney CJ, Nagaiah G, Fu P, et al. A Phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3), 233-240 (2009)
58. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol. Metab. Clin. North Am. 37(2), 511-524, xi (2008) (Pubitemid 351698088)
59. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr. Pract. 15(6), 605-611 (2009)
60. Fuente N, Mane JM, Barcelo R, et al. Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann. Oncol. 15(3), 537 (2004) (Pubitemid 38444562)
61. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17(7), 663-670 (2007) (Pubitemid 47311556)
62. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg. 231(3), 329-338 (2000)
63. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg. Oncol. 12(2), 69-90 (2003) (Pubitemid 37289013)
64. Ulisse S, Delcros JG, Baldini E, et al. Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int. J. Cancer 119(2), 275-282 (2006)
65. Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancerderived cell lines. Endocr. Relat. Cancer 15(2), 559-568 (2008) (Pubitemid 351880843)
66. Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J. Clin. Endocrinol. Metab. 85(1), 302-308 (2000) (Pubitemid 32268830)
67. Nagayama Y, Yokoi H, Takeda K, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J. Clin. Endocrinol. Metab. 85(11), 4081-4086 (2000) (Pubitemid 32055356)
68. Pacifico F, Leonardi A. Role of NF-kB in thyroid cancer. Mol. Cell Endocrinol. (2009)
69. Meng Z, Mitsutake N, Nakashima M, et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 149(11), 5357-5365 (2008)
70. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 14(10), 2534-2543 (2003) (Pubitemid 37169339)
71. Iannetti A, Pacifico F, Acquaviva R, et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl Acad. Sci. USA 105(37), 14058-14063 (2008)
72. Zhu W, Ou Y, Li Y, et al. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kB pathway. Mol. Pharmacol. 75(4), 812-819 (2009)
73. Festa M, Petrella A, Alfano S, Parente L. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kB pathway. Int. J. Cancer 124(11), 2728-2736 (2009)
74. Bonofiglio D, Qi H, Gabriele S, et al. Peroxisome proliferator-activated receptor g inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr. Relat. Cancer 15(2), 545-557 (2008) (Pubitemid 351880842)
75. Antonelli A, Ferrari SM, Fallahi P, et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol. 159(3), 283-291 (2008)
76. Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin. Endocrinol. 70(6), 946-953 (2009)
77. Hayashi N, Nakamori S, Hiraoka N, et al. Antitumor effects of peroxisome proliferator activate receptor g ligands on anaplastic thyroid carcinoma. Int. J. Oncol. 24(1), 89-95 (2004)
78. Su W, Necela BM, Fujiwara K, et al. The high affinity peroxisome proliferatoractivated receptor-g agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int. J. Cancer 123(5), 991-997 (2008)
79. Marlow LA, Reynolds LA, Cleland AS, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 69(4), 1536-1544 (2009)
80. Shimazaki N, Togashi N, Hanai M, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor g agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur. J. Cancer 44(12), 1734-1743 (2008)
81. Park JW, Zarnegar R, Kanauchi H, et al. Troglitazone, the peroxisome proliferatoractivated receptor-g agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15(3), 222-231 (2005) (Pubitemid 40418689)
82. Philips JC, Petite C, Willi JP, Buchegger F, Meier CA. Effect of peroxisome proliferator-activated receptor g agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nuclear Med. Comm. 25(12), 1183-1186 (2004) (Pubitemid 39614279)
83. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6(10), 793-810 (2007) (Pubitemid 47504871)
84. Jeong H, Kim YR, Kim KN, et al. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nuclear Med. Biol. 33(7), 875-882 (2006) (Pubitemid 44512130)
85. Lan L, Cui D, Luo Y, et al. Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro. J. Endocrinol. Invest. 32(9), 731-738 (2009)
86. Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10(1), 22-33 (2005) (Pubitemid 40171249)
87. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol. 157(3), 433-440 (2007) (Pubitemid 47256108)
88. Klopper JP, Berenz A, Hays WR, et al. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin. Cancer Res. 14(2), 589-596 (2008) (Pubitemid 351226129)
89. Gruning T, Tiepolt C, Zophel K, et al. Retinoic acid for redifferentiation of thyroid cancer -does it hold its promise? Eur. J. Endocrinol. 148(4), 395-402 (2003) (Pubitemid 36527410)
90. Short SC, Suovuori A, Cook G, Vivian G, Harmer C. A Phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol. 16(8), 569-574 (2004) (Pubitemid 39517666)
91. Du ZX, Wang HQ, Zhang HY, Gao DX. Involvement of glyceraldehyde-3- phosphate dehydrogenase in tumor necrosis factorrelated apoptosis-inducing ligand-mediated death of thyroid cancer cells. Endocrinology 148(9), 4352-4361 (2007)
92. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100(1), 24-28 (2009)
93. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003) (Pubitemid 36741588)
94. Conticello C, Adamo L, Giuffrida R, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J. Clin. Endocrinol. Metab. 92(5), 1938-1942 (2007) (Pubitemid 46997213)
95. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 99(6), 1147-1154 (2008) (Pubitemid 351676626)
96. Lin SF, Gao SP, Price DL, et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin. Cancer Res. 14(5), 1519-1528 (2008) (Pubitemid 351413937)
97. Reddi HV, Madde P, Reichert-Eberhardt AJ, et al. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther. 15(11), 750-757 (2008)
98. Libertini S, Iacuzzo I, Perruolo G, et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin. Cancer Res. 14(20), 6505-6514 (2008)
99. Lin SF, Yu Z, Riedl C, et al. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 142(6), 976-983 (2007) (Pubitemid 350193250)
100. Lin SF, Price DL, Chen CH, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J. Clin. Endocrinol. Metab. 93(11), 4403-4407 (2008) (Pubitemid 352789538)
101. Abbosh PH, Li X, Li L, et al. A conditionally replicative, Wnt/b-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Ther. 14(4), 399-408 (2007) (Pubitemid 46425783)
102. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Mol. Asp. Med. 31(2), 215-226 (2010)
103. Catalano MG, Pugliese M, Poli R, et al. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol. Rep. 21(2), 515-521 (2009)
104. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer 14(3), 839-845 (2007) (Pubitemid 350074071)
105. Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 191(2), 465-472 (2006) (Pubitemid 44830622)
106. Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 90(3), 1383-1389 (2005) (Pubitemid 40463993)
107. Noguchi H, Yamashita H, Murakami T, et al. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocrine J. 56(2), 245-249 (2009)
108. Dowlati A, Robertson K, Cooney M, et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62(12), 3408-3416 (2002) (Pubitemid 34651387)
109. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr. Opin. Oncol. 20(1), 19-24 (2008) (Pubitemid 350190977)
110. Rovere RK, Awada A. Treatment of recurrent thyroid cancers -is there a light in the horizon? Curr. Opin. Oncol. 20(3), 245-248 (2008) (Pubitemid 351507542)
111. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized Phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(6), 976-983 (2009)
112. Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 16(3), 715-731 (2009)
113. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 26(10), 1135-1145 (2008)
114. Shendure J, Stewart CJ. Cancer genomes on a shoestring budget. N. Engl. J. Med. 360(26), 2781-2783 (2009)
115. Holt RA, Jones SJ. The new paradigm of flow cell sequencing. Genome Res. 18(6), 839-846 (2008) (Pubitemid 351793056)
116. Papewalis C, Ehlers M, Schott M. Advances in cellular therapy for the treatment of thyroid cancer. J. Oncol. 2010, 179491 (2010)
117. Landriscina M, Maddalena F, Fabiano A, et al. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res. 30(2), 473-480 (2010)
118. Landriscina M, Piscazzi A, Fabiano A, et al. Targeting epidermal growth factor receptor 1 signaling in human thyroidstimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. Thyroid 19(6), 629-637 (2009)
119. Kurebayashi J, Okubo S, Yamamoto Y, et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother. Pharmacol. 58(4), 460-470 (2006) (Pubitemid 43999794)
120. Yeung SC, She M, Yang H, et al. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 92(8), 2902-2909 (2007) (Pubitemid 47236348)
121. Gregorc V, Santoro A, Bennicelli E, et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br. J. Cancer 101(2), 219-224 (2009)
122. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26(22), 3709-3714 (2008)
123. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 28(14), 2323-2330 (2010)
124. ClinicalTrials.gov www.clinicaltrials.gov (Accessed 11 June 2010)